Bioclinica acquired by private equity firm

By Melissa Fassbender contact

- Last updated on GMT

The transaction is expected to close in the fourth quarter of 2016. (Image: iStock/pichet_w)
The transaction is expected to close in the fourth quarter of 2016. (Image: iStock/pichet_w)

Related tags: Private equity

The international private equity firm, Cinven, is set to purchase Bioclinica, marking the company’s latest in a series of purchases as industry consolidation continues.

The acquisition is the first investment from the firm's €7bn ($7.92bn) Sixth Cinven Fund, which was raised to support further growth in Europe as well as across the globe. Cinven previously purchased Medpace in April 2014 for $915m. It also owns AMCo, a specialty pharmaceuticals company, and Synlab​, a clinical diagnostic laboratory.

As previously​ reported, Cinven’s move into the medical research industry follows a string of private equity investments in the market. Most recently, inVentiv canceled its planned IPO​ after the on-boarding of the global private equity investor, Advent International.

According to the company, Cinven will use its global capabilities to strengthen Bioclinica’s international operations and services, particularly in Europe and Asia. Dr. John Hubbard will continue as president and CEO and all executive officers will remain in their current positions. 

"Similar to our prior owners, Cinven sees great potential in Bioclinica and will support our vision for our long-term success in supporting our customer’s needs.​ We are very excited about the potential opportunity that comes with this transition, and see it as beginning the next stage of Bioclinica’s evolution," ​Dr. John Hubbard told us.

"Cinven is a highly-regarded company with a proven track record of taking good companies and making them great, in particular further internationalizing businesses and working with management teams to successfully execute and integrate acquisitions. This can only bring more benefits to our customers as we invest in our products and services to bring even more value to the life sciences industry​," he added.

The transaction, which follows several investments from Bioclinca, is expected to close in the fourth quarter of 2016.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more


View more